Acalabrutinib

Generic Name: Acalabrutinib

Brand Names: Calquence

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₃N_₇O_₂

CAS Number: 1420477-60-6

Unique Ingredient Identifier: I42748ELQW

Background: To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.
...

Indication: Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy. It has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphoma.

Associated Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma

Associated Therapies: -

Clinical Trials

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas

Phase 2

Recruiting

Conditions: Central Nervous System Lymphoma

Interventions: Drug: Acalabrutinib

First Posted Date: 2020-09-14

Last Posted Date: 2024-11-26

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 16

Registration Number: NCT04548648

Locations: 🇺🇸
Wake Forest University,The Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸
Moffit Cancer Center, Tampa, Florida, United States
🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

Phase 3

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: placebo
Drug: acalabrutinib
Drug: Prednisone
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin

First Posted Date: 2020-08-28

Last Posted Date: 2024-12-19

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 611

Registration Number: NCT04529772

Locations: 🇺🇦
Research Site, Zaporizhzhia, Ukraine

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Acalabrutinib
Biological: Obinutuzumab

First Posted Date: 2020-08-10

Last Posted Date: 2024-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04505254

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Phase 1

Conditions: Chronic Lymphocytic Leukemia
Non Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma

Interventions: Drug: KRT-232
Drug: acalabrutinib

First Posted Date: 2020-08-06

Last Posted Date: 2022-08-04

Lead Sponsor: Kartos Therapeutics, Inc.

Target Recruit Count: 84

Registration Number: NCT04502394

Locations: 🇰🇷
Seoul St. Mary's Hospital, Seoul, Korea, Republic of
🇵🇱
Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii, Gdansk, Poland
🇵🇱
Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii, Gdańsk, Poland

and more 42 locations

Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19

Phase 1

Terminated

Conditions: COVID-19

Interventions: Drug: Acalabrutinib

First Posted Date: 2020-08-04

Last Posted Date: 2021-11-17

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 9

Registration Number: NCT04497948

Locations: 🇧🇷
Research Site, Sao Paulo, Brazil

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

Phase 1

Completed

Conditions: Infectious Disease

Interventions: Drug: Acalabrutinib
Drug: Rabeprazole

First Posted Date: 2020-07-28

Last Posted Date: 2020-10-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 35

Registration Number: NCT04489797

Locations: 🇺🇸
Research Site, Anaheim, California, United States

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Phase 2

Recruiting

Conditions: Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma

Interventions: Drug: Acalabrutinib
Biological: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

First Posted Date: 2020-07-23

Last Posted Date: 2024-12-19

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 36

Registration Number: NCT04484012

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma

Phase 1

Recruiting

Conditions: Primary Central Nervous System Lymphoma

Interventions: Drug: Durvalumab
Drug: Acalabrutinib

First Posted Date: 2020-07-08

Last Posted Date: 2024-12-06

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 21

Registration Number: NCT04462328

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
The Ohio State University Hospital, Columbus, Ohio, United States

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Phase 2

Active, not recruiting

Conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma
Ann Arbor Stage III Grade 2 Follicular Lymphoma
Ann Arbor Stage III Grade 3 Follicular Lymphoma
Ann Arbor Stage IV Grade 1 Follicular Lymphoma
Ann Arbor Stage IV Grade 2 Follicular Lymphoma
Ann Arbor Stage IV Grade 3 Follicular Lymphoma
Grade 3a Follicular Lymphoma

Interventions: Drug: Acalabrutinib
Drug: Lenalidomide
Biological: Rituximab

First Posted Date: 2020-05-27

Last Posted Date: 2024-10-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04404088

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Acalabrutinib

First Posted Date: 2020-05-26

Last Posted Date: 2024-04-15

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 15

Registration Number: NCT04402138

Locations: 🇺🇸
Tulane University, Office of Clinical Research, New Orleans, Louisiana, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
HCA Midwest, Kansas City, Missouri, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy